Patents by Inventor Zara Safarian
Zara Safarian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7141362Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.Type: GrantFiled: October 14, 2004Date of Patent: November 28, 2006Assignee: Bio-Rad Laboratories, Inc.Inventors: Steven R. Binder, Jodi L. Goodrich, Zara Safarian
-
Patent number: 7138245Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.Type: GrantFiled: October 13, 2004Date of Patent: November 21, 2006Assignee: Bio-Rad Laboratories, Inc.Inventors: Steven R. Binder, Jodi L. Goodrich, Zara Safarian
-
Publication number: 20050106640Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.Type: ApplicationFiled: October 14, 2004Publication date: May 19, 2005Applicant: Bio-Rad Laboratories, Inc., a corporation of the state of DelawareInventors: Steven Binder, Jodi Goodrich, Zara Safarian
-
Publication number: 20050106632Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.Type: ApplicationFiled: October 13, 2004Publication date: May 19, 2005Applicant: Bio-Rad Laboratories, Inc.Inventors: Steven Binder, Jodi Goodrich, Zara Safarian
-
Patent number: 6660486Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.Type: GrantFiled: May 31, 2001Date of Patent: December 9, 2003Assignee: Bio-Rad Laboratories, Inc.Inventors: Steven R. Binder, Jodi L. Goodrich, Zara Safarian
-
Publication number: 20030113801Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.Type: ApplicationFiled: October 1, 2002Publication date: June 19, 2003Applicant: Bio-Rad Laboratories, Inc.Inventors: Steven R. Binder, Jodi L. Goodrich, Zara Safarian
-
Publication number: 20030082828Abstract: Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.Type: ApplicationFiled: May 31, 2001Publication date: May 1, 2003Inventors: Steven R. Binder, Jodi L. Goodrich, Zara Safarian
-
Patent number: 6171869Abstract: Protein-containing solutions requiring desalting and concentration are desalted and concentrated in a one step procedure. Ion exchange and ion retardation resins are used for desalting. A standard ultrafiltration device is modified to contain a mixed bed ion exchange resin and an ion retardation resin. The sample is introduced to the modified ultrafiltration unit and subjected to centrifugation. The centrifugal force drives low molecular weight constituents through the ultrafiltration membrane and draws liquid containing ion exchange products away from contact with the combined resins thereby driving the reaction to achieve a more complete desalting and concentration of the proteins in the sample solution. The proteins in the sample are thus concentrated and desalted simultaneously.Type: GrantFiled: April 8, 1997Date of Patent: January 9, 2001Assignee: Beckman Coulter, Inc.Inventors: Zara Safarian, Cynthia R. Blessum
-
Patent number: 5677422Abstract: A method for making a homogeneous succinylated polypeptide is disclosed. The method can be carried out by adding a succinyl-containing compound to a polypeptide solution, followed by raising the pH of the polypeptide solution to a pH of between about pH 10 to pH 12.5. The succinylation reaction between the succinyl-containing compound and free amino groups of the polypeptide is essentially complete upon raising the polypeptide solution pH to the alkaline pH.Type: GrantFiled: August 22, 1996Date of Patent: October 14, 1997Assignee: Beckman Instruments, Inc.Inventors: Zara Safarian, Hann-Ping Wang
-
Patent number: 5599433Abstract: A buffer and method useful for the analysis of glycoproteins by capillary zone electrophoresis. The buffer comprises water, a sugar complexing compound, a base compound for adjusting the pH, and a zwitterionic compound. An embodiment of the buffer comprises sodium borate as the complexing compound, sodium hydroxide as the base, and 3-cyclohexylamino-1-propanesulfonic acid as the zwitterionic compound. In the method, a selected glycoprotein is subjected to capillary zone electrophoresis. The proportion or the amount of the glycoprotein is determined by quantitative analysis of the resulting electropherogram.Type: GrantFiled: January 17, 1995Date of Patent: February 4, 1997Assignee: Beckman Instruments, Inc.Inventors: Nida Keo, Zara Safarian, Cheng-Ming Liu, Hann-Ping Wang
-
Patent number: 5431793Abstract: A method useful for determining the content of a first hemoglobin in a blood sample which also contains other forms of hemoglobin is based on capillary electrophoresis. In the method, a specific binding partner to the first form of hemoglobin is added to the sample, and the sample is then subjected to capillary electrophoresis. The method is particularly suited for the determination of the percentage of Hb A.sub.1c in a blood sample using anti-Hb A.sub.1c antibody.Type: GrantFiled: July 29, 1994Date of Patent: July 11, 1995Assignee: Beckman Instruments, Inc.Inventors: Hann-Ping Wang, Zara Safarian